Novel anti-tumor strategies: targeting the crosstalk between cancer stem cells and cancer-associated fibroblasts to resist drug resistance [0.03%]
新颖的抗肿瘤策略：靶向作用于癌症干细胞和癌相关成纤维细胞间的相互作用以克服耐药性
Yang Shen,Yuting Sun,Xurui Li et al.
Yang Shen et al.
The reciprocal feedback between cancer stem cells (CSCs) and cancer-associated fibroblasts (CAFs) is increasingly recognized as a driver of therapeutic resistance and tumor evolution. According to the "soil and seed" hypothesis, CAFs create...
Circular RNA hsa-circ-0001030 suppresses proliferation and cisplatin tolerance in TSCC via interaction with PKM2 [0.03%]
Circular RNA hsa_circ_0001030通过与PKM2互作抑制舌鳞癌的增殖和顺铂耐药性
Haojie Yang,Yingzhe Yan,Zicong Tan et al.
Haojie Yang et al.
Aim: Cisplatin resistance remains a major obstacle to the effective treatment of tongue squamous cell carcinoma (TSCC). This study is dedicated to elucidating the role and mechanism of circular RNA (circRNA) hsa-circ-0001030 in modulating c...
Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transporters [0.03%]
识别抗体药物偶联物有效载荷作为ATP结合盒药物外排转运蛋白的底物
Jacob S Roth,Hui Guo,Lu Chen et al.
Jacob S Roth et al.
Aim: Antibody-drug conjugates (ADCs) feature an antibody recognizing a specific protein joined to a potent toxic payload. Numerous ADCs have received U.S. Food and Drug Administration (FDA) approval; however, clinical resistance arises. Res...
MicroRNAs as key regulators of cancer drug resistance: insights and future directions in chemotherapy, targeted-therapy, radiotherapy, and immunotherapy [0.03%]
microRNA作为调控癌症药物抗性的重要因子：化疗、靶向治疗、放疗和免疫疗法的新视野与未来方向
Michael Attathikhun,Ancuta Jurj,George A Calin
Michael Attathikhun
Cancer therapy remains an active field of investigation, particularly in understanding and overcoming therapy resistance. Small non-coding RNAs, such as microRNAs (miRNAs), are emerging as key regulators of cancer survival, progression, pro...
Osimertinib acquired resistance among patients with EGFR-mutated NSCLC: from molecular mechanisms to clinical therapeutic strategies [0.03%]
奥西替尼耐药的EGFR突变非小细胞肺癌患者的分子机制及临床治疗策略
Ren Wang,Yuanhang Chen,Liping Li et al.
Ren Wang et al.
Non-small-cell lung cancer (NSCLC) remains the leading cause of global cancer-related mortality. NSCLC patients with epidermal growth factor receptor (EGFR) mutations benefit substantially from treatment with EGFR tyrosine kinase inhibitors...
Unraveling resistance to immune checkpoint inhibitors in HNSCC: from mechanisms to combination therapies [0.03%]
解构头颈部癌症对免疫检查点抑制剂产生耐药性的机制并结合综合疗法提高疗效
Wenchao Zhao,Qingqing Luo,Bowen Yuan et al.
Wenchao Zhao et al.
Head and neck squamous cell carcinoma (HNSCC), which arises from the mucosal linings of the oral cavity, pharynx, and larynx, represents the most prevalent head and neck malignancy. This cancer is notable for its elevated incidence and subs...
Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcoma [0.03%]
克服耐药性：融合阴性的横纹肌肉瘤治疗新策略
Silvia Codenotti,Francesco Marampon,Francesca Megiorni et al.
Silvia Codenotti et al.
Rhabdomyosarcomas (RMS) are aggressive pediatric soft tissue tumors. The fusion-negative subtype (FN-RMS) is characterized by RAS pathway mutations and genomic instability. While standard chemotherapies - vincristine, actinomycin D, and alk...
Overcoming cancer drug resistance through small-molecule targeting of HSP90 and HSP70 [0.03%]
通过小分子靶向HSP90和HSP70克服癌症药物耐药性
Ren-Duan Cai,Ming-Jing Lin,Qing-Mei Ye
Ren-Duan Cai
Heat shock proteins (HSPs) play a critical role in cancer progression and drug resistance by stabilizing oncoproteins, enhancing DNA repair, and modulating apoptosis pathways. In particular, HSP90 and HSP70 have been implicated in maintaini...
Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies [0.03%]
癌症治疗中抗体药物偶联物抗性机制：分子基础和治疗策略
Yue Hao,Zhengbo Song
Yue Hao
Antibody-drug conjugates (ADCs) have emerged as a transformative class in oncology, integrating the target specificity of monoclonal antibodies with the potent cytotoxicity of small-molecule payloads. By harnessing tumor-specific antigen re...
Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: an update [0.03%]
靶向肿瘤引流淋巴结以克服癌症免疫治疗的耐药性：最新研究进展
Jianan Lu,Jiangnan Yu,Tuo Xu et al.
Jianan Lu et al.
Immune checkpoint inhibitor (ICI) resistance often stems from intratumoral T cell dysfunction. This review focuses on both tumor-intrinsic and tumor-draining lymph node (TDLN)-centric resistance mechanisms. We detail how specific defects wi...